GEAP202416596A - Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof - Google Patents
Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereofInfo
- Publication number
- GEAP202416596A GEAP202416596A GEAP202416596A GEAP2024016596A GEAP202416596A GE AP202416596 A GEAP202416596 A GE AP202416596A GE AP202416596 A GEAP202416596 A GE AP202416596A GE AP2024016596 A GEAP2024016596 A GE AP2024016596A GE AP202416596 A GEAP202416596 A GE AP202416596A
- Authority
- GE
- Georgia
- Prior art keywords
- tl1a
- compositions
- tnf
- ligand
- humanized antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163150825P | 2021-02-18 | 2021-02-18 | |
| US202163180892P | 2021-04-28 | 2021-04-28 | |
| US202163226037P | 2021-07-27 | 2021-07-27 | |
| US202163285781P | 2021-12-03 | 2021-12-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GEAP202416596A true GEAP202416596A (en) | 2024-10-28 |
Family
ID=82931032
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GEAP202416596A GEAP202416596A (en) | 2021-02-18 | 2022-02-17 | Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof |
| GEAP202316354A GEAP202316354A (en) | 2021-02-18 | 2022-02-17 | Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GEAP202316354A GEAP202316354A (en) | 2021-02-18 | 2022-02-17 | Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20240309104A1 (https=) |
| EP (1) | EP4294444A4 (https=) |
| JP (1) | JP2024506940A (https=) |
| KR (1) | KR20230157973A (https=) |
| AU (1) | AU2022223420A1 (https=) |
| BR (1) | BR112023016672A2 (https=) |
| CA (1) | CA3207817A1 (https=) |
| CL (1) | CL2023002424A1 (https=) |
| CO (1) | CO2023011969A2 (https=) |
| CR (1) | CR20230436A (https=) |
| DO (1) | DOP2023000162A (https=) |
| EC (1) | ECSP23070237A (https=) |
| GE (2) | GEAP202416596A (https=) |
| IL (1) | IL305312A (https=) |
| JO (1) | JOP20230185A1 (https=) |
| MX (1) | MX2023009622A (https=) |
| PE (1) | PE20231681A1 (https=) |
| TW (1) | TW202246322A (https=) |
| WO (1) | WO2022178159A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102343212B1 (ko) | 2013-03-27 | 2021-12-23 | 세다르스-신나이 메디칼 센터 | Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전 |
| TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| JP2022533956A (ja) | 2019-05-14 | 2022-07-27 | プロメテウス バイオサイエンシーズ，インク． | Ｔｌ１ａ患者を選択する方法、システム、およびデバイス |
| KR20220103721A (ko) | 2019-10-24 | 2022-07-22 | 프로메테우스 바이오사이언시즈, 인크. | Tnf 유사 리간드 1a(tl1a)에 대한 인간화 항체 및 그의 용도 |
| EP4637819A1 (en) * | 2022-12-22 | 2025-10-29 | Prometheus Biosciences, Inc. | Methods of treating inflammatory diseases with combination of tl1a inhibitors and s1pr inhibitors |
| WO2024173838A2 (en) * | 2023-02-17 | 2024-08-22 | Prometheus Biosciences, Inc. | Anti-tl1a antibody compositions and methods of treatment in the bile duct |
| CN121843714A (zh) | 2023-08-11 | 2026-04-10 | 派拉冈医疗公司 | Tl1a结合抗体及使用方法 |
| US12473370B2 (en) | 2023-10-03 | 2025-11-18 | Absci Corporation | TL1A associated antibody compositions and methods of use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3375B1 (ar) * | 2010-11-08 | 2019-03-13 | Regeneron Pharma | أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a) |
| UY35148A (es) * | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| MX388027B (es) * | 2013-11-13 | 2025-03-19 | Pfizer | Anticuerpos específicos para el ligando 1a tipo factor de necrosis tumoral y composiciones y usos de los mismos. |
| KR102417687B1 (ko) * | 2016-05-09 | 2022-07-07 | 브리스톨-마이어스 스큅 컴퍼니 | Tl1a 항체 및 그의 용도 |
| MY191324A (en) * | 2016-10-26 | 2022-06-15 | Cedars Sinai Medical Center | Neutralizing anti-tl1a monoclonal antibodies |
| JP7332627B2 (ja) * | 2018-04-25 | 2023-08-23 | プロメテウス バイオサイエンシーズ，インク． | 最適化された抗ｔｌ１ａ抗体 |
| WO2021081365A1 (en) * | 2019-10-24 | 2021-04-29 | Prometheus Biosciences, Inc. | Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof |
-
2022
- 2022-02-17 AU AU2022223420A patent/AU2022223420A1/en active Pending
- 2022-02-17 IL IL305312A patent/IL305312A/en unknown
- 2022-02-17 WO PCT/US2022/016841 patent/WO2022178159A1/en not_active Ceased
- 2022-02-17 TW TW111105898A patent/TW202246322A/zh unknown
- 2022-02-17 BR BR112023016672A patent/BR112023016672A2/pt unknown
- 2022-02-17 KR KR1020237031689A patent/KR20230157973A/ko active Pending
- 2022-02-17 JP JP2023549820A patent/JP2024506940A/ja active Pending
- 2022-02-17 MX MX2023009622A patent/MX2023009622A/es unknown
- 2022-02-17 CR CR20230436A patent/CR20230436A/es unknown
- 2022-02-17 PE PE2023002389A patent/PE20231681A1/es unknown
- 2022-02-17 CA CA3207817A patent/CA3207817A1/en active Pending
- 2022-02-17 EP EP22756949.8A patent/EP4294444A4/en active Pending
- 2022-02-17 GE GEAP202416596A patent/GEAP202416596A/en unknown
- 2022-02-17 US US18/546,938 patent/US20240309104A1/en active Pending
- 2022-02-17 GE GEAP202316354A patent/GEAP202316354A/en unknown
-
2023
- 2023-08-09 JO JOJO/P/2023/0185A patent/JOP20230185A1/ar unknown
- 2023-08-16 CL CL2023002424A patent/CL2023002424A1/es unknown
- 2023-08-17 DO DO2023000162A patent/DOP2023000162A/es unknown
- 2023-09-08 CO CONC2023/0011969A patent/CO2023011969A2/es unknown
- 2023-09-14 EC ECSENADI202370237A patent/ECSP23070237A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3207817A1 (en) | 2022-08-25 |
| BR112023016672A2 (pt) | 2023-11-21 |
| TW202246322A (zh) | 2022-12-01 |
| JOP20230185A1 (ar) | 2023-08-09 |
| DOP2023000162A (es) | 2023-10-15 |
| WO2022178159A1 (en) | 2022-08-25 |
| GEAP202316354A (en) | 2023-12-25 |
| MX2023009622A (es) | 2023-08-28 |
| IL305312A (en) | 2023-10-01 |
| CO2023011969A2 (es) | 2023-09-29 |
| AU2022223420A1 (en) | 2023-09-21 |
| JP2024506940A (ja) | 2024-02-15 |
| EP4294444A1 (en) | 2023-12-27 |
| CR20230436A (es) | 2023-11-01 |
| KR20230157973A (ko) | 2023-11-17 |
| EP4294444A4 (en) | 2025-04-16 |
| PE20231681A1 (es) | 2023-10-19 |
| US20240309104A1 (en) | 2024-09-19 |
| ECSP23070237A (es) | 2023-10-31 |
| CL2023002424A1 (es) | 2024-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEAP202416596A (en) | Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof | |
| ZA202204557B (en) | Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof | |
| CL2022001016A1 (es) | Anticuerpos humanizados contra el ligando 1a de tipo tnf (tl1a) y usos de los mismos | |
| GEAP202516710A (en) | Anti-cd30l antibodies and uses thereof | |
| EA202092899A1 (ru) | Гетероарильные соединения для лечения болезни гентингтона | |
| EA202092896A1 (ru) | Гетероциклические и гетероарильные соединения для лечения болезни гентингтона | |
| WO2019209995A3 (en) | Optimized anti-tl1a antibodies | |
| MY191324A (en) | Neutralizing anti-tl1a monoclonal antibodies | |
| EA202092001A1 (ru) | Соединения для лечения болезни гентингтона | |
| EA201892790A1 (ru) | Применение 2-замещенных индазолов для лечения и профилактики аутоиммунных заболеваний | |
| EA201200689A1 (ru) | Способ уменьшения желудочно-кишечного воспаления с помощью бактерий bifidobacterium animalis или кисло-молочного продукта, содержащего такие бактерии | |
| JOP20210030A1 (ar) | مثبطات تفاعل البروتين-بروتين KEAP1-Nrf2 | |
| MX2022008951A (es) | Composiciones de inhibidores de molecula peque?a del receptor de quimiocina c-c tipo 9 (ccr9) y anticuerpos bloqueadores anti- 4?7 integrina para usarse en el tratamiento de enfermedad inflamatoria de intestino. | |
| MX2025001038A (es) | Anticuerpos anti-cd30l, formulaciones de estos, y uso de los mismos | |
| BR112022019958A2 (pt) | Composições e métodos para o tratamento de doenças inflamatórias do intestino utilizando anticorpos inibidores de ccr9 e anticorpos de bloqueio anti-il -23 | |
| CL2025000202A1 (es) | Anticuerpos anti-tl1a para el tratamiento de la colitis ulcerosa y la enfermedad de crohn | |
| MX2022011953A (es) | Composicion para controlar el olor y alfombra que tiene una propiedad durable de control de olor. | |
| EA200900602A1 (ru) | Применение альфа 1-тимозина для приготовления лекарства для профилактики и лечения аутоиммунных заболеваний | |
| DOP2023000160A (es) | Anticuerpos anti-cd30l y usos de estos | |
| EA202190578A1 (ru) | ИНГИБИТОРЫ БЕЛОК-БЕЛКОВОГО ВЗАИМОДЕЙСТВИЯ KEAP1-Nrf2 | |
| TW202613167A (zh) | 使用抗ｔｌ１ａ抗體治療發炎性腸病之方法 | |
| HK40101325A (en) | Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof |